Liver surgery for noncolorectal metastases  by Di Carlo, Isidoro
GUEST EDITORIAL
Liver surgery for noncolorectal nonneuroendocrine metastases
The place of surgery in the management of resectable
liver metastases of colorectal malignancies has been
recognized and well established. Moreover, coopera-
tion between surgeons and oncologists permits
shrinkage of unresectable liver metastases, making
these suitable for surgical treatment. The clear
distinction between resectable and unresectable me-
tastases in this field is probably near to becoming
obsolete. For symptomatic metastatic neuroendocrine
tumors, hepatic resection, including liver transplanta-
tion, may offer long-term palliation in many cases and
cure in some others.
In contrast, the role of hepatic surgery in patients
with liver metastases from noncolorectal nonneuroen-
docrine (NCRNNE) carcinoma is not well defined.
There are many reasons for this lack of clarity. Many
reports include neuroendocrine patients in their
analysis and consequently alter survival data. Indeed,
most series are not comparable in terms of mid- and
long-term (tumor-free) survival, as they include
patients with NCRNNE hepatic metastases from
different primary malignancies, different tumoral
behaviour and different frequency of isolated hepatic
metastases, different sensitivity to neoadjuvant or
adjuvant therapy (chemotherapy or radiotherapy)
and different length of delay between the diagnosis
of the primary tumor and the liver metastases
(synchronous or metachronous). Further, most of
the studies span at least 10 years, so the role of the
chemotherapy should be carefully considered, since
the protocols have evolved rapidly during this time.
Due to these heterogeneous characteristics, the
conclusions of many comprehensive studies are
that prognostic factors for liver metastases from
NCRNNE remain uncertain.
In recent years, despite the poor results, liver
metastases suitable for surgery have been operated.
The main reasons for this attitude include the
refinements in preoperative work-up, anesthesiology
management, perioperative care, and surgical techni-
que that make liver surgery reasonably safe; decreas-
ing operative mortality to approximately 1% in
tertiary referring centres. Also, there are no data
that actually suggest the usefulness of alternative
treatments for NCRNNE liver metastases, so this
reinforces the role of surgery.
In the absence of certain indications, the patients
have been treated surgically and, as for large hepatic
metastases from colorectal cancer where it is now
possible, after chemotherapy, to carry out a hepatic
resection resulting in long survival, a more aggressive
surgical approach has been observed. Since more
accurate prognostic indications are still mandatory,
the aggressive policy used by some surgeons and
oncologists, in relation to metastases confined to the
liver, should be moderate considering generic vari-
ables, such as disease-free interval (DFI) from the
primary tumor. The DFI between treatment of the
primary tumor and the development of liver metas-
tasis is viewed as a surrogate marker for tumor
biology. Twelve months is considered as generic
minimum period between primary tumor and sec-
ondary disease to give an indication for surgery for
liver metastases. After this first year, any further time
interval should be considered as a progressively
increasing positive prognostic factor. A longer DFI
is believed to indicate less aggressive tumor biology.
The role of liver resection for NCRNNE liver
metastases is still a matter of discussion, mostly
because there only small studies have been carried
out in this field and the conclusive outcomes are
collective and not specific for each type of tumor.
Since different primary tumor types have different
underlying tumor biology, the ideal study should
concentrate on only one tumor type to allow mean-
ingful conclusions. This is why in recent years, some
studies have started to analyze the NCRNNE liver
metastases only in relation to the primary tumor, to
improve knowledge and satisfy more questions. How-
ever, for some types of metastases the number of cases
reported in a comprehensive review or separately is
still small and, even if the results are encouraging,
more data are necessary to have a safe indication,
especially for metastases originating from primary
cancer considered to have a poor prognosis.
As regards pancreatic cancer, good survival rates
after an aggressive approach (including pancreatic and
hepatic combined resection) have been reported.
However, the small number of long-term survivors
had cystoadenocarcinoma as primary tumor, and
the biological behavior of this type may be different
from pancreatic ductal adenocarcinoma. This aggres-
sive approach needs validation reports and a more
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extensive number of patients. For isolated liver
metastases from pancreatic cancer, liver resection
might be an effective treatment for highly selected
patients (i.e. single metastases, DFI /24 months),
but further specific studies are necessary to better
clarify the role of hepatic resection.
Liver metastasis from gastric cancer is usually
considered a poor prognostic factor, but recent
studies based on specific metastases from this kind
of tumor began to give us some defined indication.
Survival after hepatic resection for gastric cancer
metastases is poor, but long-term survivors exist, so
careful selection of patients is mandatory. Hepatic
resection is indicated in case of solitary and meta-
chronous metastasis and when a complete resection
can be performed safely. Patients with optimum
prognosis are those with a primary tumor located at
the antrum, without lymphatic or venous invasion,
and with a minimum DFI of 1 year.
The indication for hepatic surgery in patients with
liver metastases from ovarian cancer is similar to that
of patients with diffuse metastatic disease: the two
most important factors affecting the recommendation
for surgical resection are the ability to achieve overall
optimal cytoreduction and a minimum of 1 year of
DFI. Randomized studies are needed to evaluate the
role of the surgery beyond chemotherapy and also
whether the similarity of ovarian cancer and colorectal
carcinoma suggests benefit for patients with meta-
static ovarian cancer.
For liver metastases from breast cancer, surgery is
indicated for patients at low risk, with liver metastases
completely resectable and with no extrahepatic dis-
ease. Other positive prognostic factors are a DFI
/12 months, less than four nodules and a positive
hormone receptor status. Still, if good results have
been achieved, surgery must be considered as a part
of a multimodal approach with endocrine and
chemotherapic treatment, and an objective response
or a stabilization after chemotherapy is always re-
quested before surgery. The patients are frequently
referred to the surgeon after numerous courses of
chemotherapy, which definitively impair liver func-
tion, exacerbating the risk of hepatectomy. That is
why functional tests or decisional schemes, as used for
cirrhotic patients, have been utilized to avoid post-
operative liver insufficiency.
Testicular cancer metastasizing to the liver is mainly
cured by chemotherapy. After chemotherapy, if
metastatic lesions are still present on radiography
and serum markers are normal, the patient can be
submitted to surgical resection. The best results are
achieved when there is no evidence of germ cell cancer
in the histological specimen, reaching survival rates of
89% at 4 years without relapses of disease.
The key to achieving long survival after hepatic
resection of metastases from sarcomas is an R0
resection. However, the most important independent
predictor of a good outcome is a DFI from primary
tumor of /2 years. In the field of sarcomas, GISTs
must be distinguished because neoadjuvant/adjuvant
treatment with Imatinib can allow a down-staging and
an improvement of overall survival.
Patients affected by liver metastases from kidney
cancer can achieve significant survival after hepatic
resection, if the primary tumor is free of invasion, the
DFI is /24 months, the diameter of lesion is B/5 cm
and a radical resection is possible.
Patients affected by liver metastases from adrenal
cancer can achieve good survival after complete
hepatic resection of metachronous metastases in case
of a minimum DFI from the primary tumors of
12 months.
Liver metastases from lung cancer can be treated in
the absence of extrahepatic disease with a minimum
DFI of 12 months.
In this special issue of HPB focusing on surgical
indication for NCRNNE liver metastases, the surgical
ratio for this rapidly evolving field is addressed. This
issue cannot provide a complete exposure of all types
of tumors, but the most frequent are analyzed in order
to better address these patients to the right treatment.
Each of the contributors discusses indications for
surgery and its result on liver metastases from
different primary tumors. They discuss the literature
data and, where possible, their personal results. The
authors of this issue have demonstrated that hepatic
resections are more and more indicated and, in
selected patients, the oncologic results seem to be
very encouraging.
I am sincerely grateful to all the authors for their
outstanding effort in contributing to this issue, and to
the editor for permitting me to realize this project.
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